Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ACRS
#2978
Aclaris Therapeutics, Inc.
3.9
2
USD
+0.51%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+0.51%
Changement Mensuel
+8.59%
Evolution sur 6 mois
+111.89%
Changement Annuel
+232.20%
Clôture Précédente
3.9
0
Open
3.9
2
Bid
Ask
Low
3.9
2
High
3.9
2
Volume
41
Marchés
Actions des Marchés US
Soins de Santé
ACRS
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
51.8 M
61.28 M
66.69 M
70.93 M
107.92 M
120.6 M
—
Valuation ratios
Enterprise value
327.26 M
877.14 M
959.79 M
34.59 M
243.07 M
343.03 M
787.37 M
Price to earnings ratio
—
-9.09
-11.33
-0.83
-1.45
-5.68
-8.75
Price to sales ratio
—
122
33.03
2.35
10.24
47.14
71.67
Price to cash flow ratio
—
-15.82
-14.55
-0.94
-9.55
-7.83
295.07
Price to book ratio
—
4.18
4.97
0.47
1.23
3.58
4.4
Enterprise value to EBITDA ratio
-17.26
-43.24
728.21
-2.55
-29.76
-21.73
-87.29
Profitability ratios
Return on assets %
-0.72
-0.36
-0.34
-0.45
-0.6
-0.4
-0.36
Return on equity %
-1.35
-0.46
-0.44
-0.56
-0.85
-0.63
-0.54
Return on invested capital %
-1 118.27
-1 086.25
-958.37
-798.73
-657.83
-351.69
-346.2
Gross margin %
20.81
30.29
86.48
89.05
85.09
73.28
278.85
Operating margin %
-785.44
-1 327.07
-302.01
-311.55
-758.18
-975.91
-4 554.14
EBITDA margin %
-279.93
-295.39
4.43
-43.39
-43.63
-201.67
-997.97
Net margin %
-787.03
-1 343.96
-292.11
-283.15
-705.48
-829.58
-3 876.59
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
3.87
8.94
10.55
4.16
3.99
3.36
16.23
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.08
0.04
0.12
0.14
0.09
0.04
0.04
Solvency ratios
Debt to assets ratio
0.2
0.05
—
—
—
—
—
Debt to equity ratio
0.38
0.07
—
—
—
—
—
Long term debt to total assets ratio
0.15
0.04
—
—
—
—
—
Long term debt to total equity ratio
0.28
0.05
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-0.92
-1.04
-1.12
-0.26
-0.38
-0.38
EBIT per share
—
-1.58
-1.38
-1.39
-1.84
-0.62
-0.62
EBITDA per share
—
-0.35
0.02
-0.19
-0.11
-0.13
-0.13
Total debt per share
—
0.24
—
—
—
—
—
Cash per share
—
3.98
3.52
2.61
2.64
1.24
5.63
Net current asset value per share
—
3.61
3.55
1.85
1.63
0.79
3.35
Tangible book value per share
—
3.35
2.92
2.25
2.01
0.84
4.07
Working capital per share
—
3.21
3.21
1.4
1.22
0.55
2.51
Book value per share
—
3.48
3.03
2.25
2.01
0.84
4.07
Nouvelles
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
H.C. Wainwright maintient sa recommandation d’achat sur Aclaris après les progrès de l’essai
Aclaris termine le recrutement pour son essai sur la dermatite atopique
H.C. Wainwright réitère sa recommandation d’achat sur Aclaris Therapeutics
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright
Stifel relève l’objectif de cours d’Aclaris Therapeutics à 3$
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Le BPA de Aclaris Therapeutics Inc a manqué les attentes de 0,01$, le CA en dessous des prévisions
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates